Logo
Close
Your free order overview
    You currently have not items to display
Logo
Close
Your contact details
Title
Gender
First Name*
Last Name*
Email*
Telephone
Country
Street
Number (+ Bus)
City
Postal code

* required fields

Logo
Close
Order completed!

Thank you

Thank you for choosing Janssen Medical Cloud for ordering your materials.

Back to Janssen Medical Cloud
open
This page is intended for healthcare professionals in [COUNTRY] only
PONVORY® is indicated for the treatment of adult patients with RMS with active disease defined by clinical or imaging features[2]

PONVORY® is the first oral DMT that proved superiority in reducing relapses and lesions against an active oral comparator, teriflunomide, in a large Phase III study[2][3]

Discover the key clinical outcomes from the pivotal Phase III study and download a summary.

Gain insight on how PONVORY® offers convenience and flexibility that can be integral to treatment.

Access prescribing resources to help you prescribe PONVORY® with confidence.

Join the growing number of healthcare professionals that benefit from a wide range of online services:

illustration3
illustration1
illustration2
Information on PONVORY® to support RMS patient care
Access to useful medical and scientific resources
The latest scientific data and treatment developments in PONVORY®

Discover how PONVORY® could meet the needs of newly-diagnosed patients with RMS

Discover how PONVORY® could meet the needs of newly-diagnosed patients with RMS

DMT=disease-modifying therapy

© JOHNSON & JOHNSON MIDDLE EAST FZ-LLC (QATAR). THIS SITE IS PUBLISHED BY JANSSEN PHARMACEUTICALS. IT IS INTENDED FOR HEALTHCARE PROFESSIONAL AUDIENCE IN QATAR ONLY.
Privacy PolicyLegal NoticeCookie Policy
Logo